Immune Repertoire Sequencing - Company Evaluation Report, 2025
The Immune Repertoire Sequencing Companies Quadrant is a comprehensive industry analysis that provides valuable insights into the global market for Immune Repertoire Sequencing. This quadrant offers a detailed evaluation of key market players, technological advancements, product innovations, and industry trends. MarketsandMarkets 360 Quadrants evaluated over 102 companies, of which the Top 15 Immune Repertoire Sequencing Companies were categorized and recognized as quadrant leaders.
Immune repertoire sequencing is a powerful application of next-generation sequencing (NGS) used to profile the vast diversity of immune cells in the body. It provides a high-resolution snapshot of an individual's adaptive immune system by sequencing the genes that code for T-cell receptors (TCRs) and B-cell receptors (BCRs). This collection of millions of unique receptors, known as the immune repertoire, holds a detailed record of a person's past and ongoing responses to pathogens, vaccines, and diseases like cancer, offering profound insights into their immunological status.
The market is primarily driven by advancements in immuno-oncology and personalized medicine. Researchers and clinicians use this technology to understand how a patient's immune system is responding to a tumor, to discover novel biomarkers for predicting treatment success, and to develop targeted immunotherapies like CAR-T cells. The technology is also critical in vaccine development for assessing efficacy, in monitoring infectious diseases, and in studying the mechanisms behind autoimmune disorders. The global push towards precision medicine, tailored to an individual's unique genetic and immune profile, is a major catalyst for market growth.
Despite its potential, the field faces significant challenges. The immense complexity of the generated data requires sophisticated bioinformatics tools and skilled analysts to interpret, creating a potential bottleneck. The high cost associated with NGS equipment and reagents, while decreasing, still limits access for many research institutions. Furthermore, a lack of standardization in experimental protocols and data analysis pipelines across different laboratories can make it difficult to compare results, highlighting a need for greater consensus to ensure the reproducibility and reliability of findings.
The 360 Quadrant maps the Immune Repertoire Sequencing companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Immune Repertoire Sequencing quadrant. The top criteria for product footprint evaluation included Product [Assay Kits & Reagents (TCR Kits [Human TCR Kits, Mouse TCR Kits], BCR Kits [Human BCR Kits, Mouse BCR Kits], Other Assay Kits & Reagents), Instruments & Software], Application [Research Applications, Drug Discovery & Development, Clinical Diagnostics], Product, Technology [Sequencing Technologies (Bulk Sequencing (Multi-cell) Technologies, Single-cell Sequencing Technologies), Library Preparation Technologies, Bioinformatics & Data Analysis Technologies], End User [Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Other End Users], Service- Workflow [Pre-sequencing Services, Sequencing Services, Data Analysis Services], Service- End User [Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Other End Users].
Key Players:
Major vendors in the Immune Repertoire Sequencing market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), PacBio (US), Oxford Nanopore Technologies PLC (UK), 10X Genomics (US), Agilent Technologies (US), Danaher Corporation (US), Takara Bio Inc. (Japan), Azenta US Inc. (US), Adaptive Biotechnologies (US), BGI Group (China), Personalis, Inc. (US), QIAGEN (Netherlands), Tecan Trading AG (Switzerland), and Creative Biolabs (US). These companies are actively investing in research and development, forming strategic partnerships, and engaging in collaborative initiatives to drive innovation, expand their global footprint, and maintain a competitive edge in this rapidly evolving market.
Top three companies:
Illumina, Inc. (US)
Illumina is the world's dominant leader in DNA sequencing, and its short-read technology has been foundational to the genomics revolution. The company provides a comprehensive portfolio of sequencing instruments, from desktop to population-scale platforms, with a business model driven by high-margin, recurring consumable sales. Following its divestiture of GRAIL, Illumina’s strategy is intensely focused on its core sequencing business, driving down costs and pushing for broader adoption in clinical diagnostics, especially oncology. By continuously innovating its platforms, Illumina aims to defend its massive market share and power the future of genomic medicine.
Thermo Fisher Scientific Inc. (US)
Thermo Fisher Scientific is the world leader in serving science, with an immense portfolio of instruments, consumables, and services. In the genomics space, it competes directly with other leaders through its Ion Torrent semiconductor sequencing platform, which offers advantages in speed and targeted applications. Strategically, Thermo Fisher embeds its genomic solutions within its broader life sciences ecosystem, supporting customers from research to diagnostics and biopharma production. By offering a comprehensive, multi-technology approach, the company maintains its powerful position as an end-to-end partner for the entire scientific community, including researchers in India.
PacBio (US)
PacBio is the leading provider of high-fidelity (HiFi) long-read DNA sequencing technology. Unlike short-read methods, its platforms excel at resolving complex genomic regions, providing a completer and more accurate picture of genomes. The company’s core strategy is to drive the adoption of its HiFi sequencing from a research niche into mainstream clinical and discovery applications. By continuously increasing the throughput and lowering the cost of its systems, PacBio is making a compelling case for the value of high-quality, long-read data, solidifying its position as a key innovator in the genomics landscape.
Immune repertoire sequencing is a powerful application of next-generation sequencing (NGS) used to profile the vast diversity of immune cells in the body. It provides a high-resolution snapshot of an individual's adaptive immune system by sequencing the genes that code for T-cell receptors (TCRs) and B-cell receptors (BCRs). This collection of millions of unique receptors, known as the immune repertoire, holds a detailed record of a person's past and ongoing responses to pathogens, vaccines, and diseases like cancer, offering profound insights into their immunological status.
The market is primarily driven by advancements in immuno-oncology and personalized medicine. Researchers and clinicians use this technology to understand how a patient's immune system is responding to a tumor, to discover novel biomarkers for predicting treatment success, and to develop targeted immunotherapies like CAR-T cells. The technology is also critical in vaccine development for assessing efficacy, in monitoring infectious diseases, and in studying the mechanisms behind autoimmune disorders. The global push towards precision medicine, tailored to an individual's unique genetic and immune profile, is a major catalyst for market growth.
Despite its potential, the field faces significant challenges. The immense complexity of the generated data requires sophisticated bioinformatics tools and skilled analysts to interpret, creating a potential bottleneck. The high cost associated with NGS equipment and reagents, while decreasing, still limits access for many research institutions. Furthermore, a lack of standardization in experimental protocols and data analysis pipelines across different laboratories can make it difficult to compare results, highlighting a need for greater consensus to ensure the reproducibility and reliability of findings.
The 360 Quadrant maps the Immune Repertoire Sequencing companies based on criteria such as revenue, geographic presence, growth strategies, investments, and sales strategies for the market presence of the Immune Repertoire Sequencing quadrant. The top criteria for product footprint evaluation included Product [Assay Kits & Reagents (TCR Kits [Human TCR Kits, Mouse TCR Kits], BCR Kits [Human BCR Kits, Mouse BCR Kits], Other Assay Kits & Reagents), Instruments & Software], Application [Research Applications, Drug Discovery & Development, Clinical Diagnostics], Product, Technology [Sequencing Technologies (Bulk Sequencing (Multi-cell) Technologies, Single-cell Sequencing Technologies), Library Preparation Technologies, Bioinformatics & Data Analysis Technologies], End User [Academic & Research Institutes, Pharmaceutical & Biotechnology Companies, Other End Users], Service- Workflow [Pre-sequencing Services, Sequencing Services, Data Analysis Services], Service- End User [Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Other End Users].
Key Players:
Major vendors in the Immune Repertoire Sequencing market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), PacBio (US), Oxford Nanopore Technologies PLC (UK), 10X Genomics (US), Agilent Technologies (US), Danaher Corporation (US), Takara Bio Inc. (Japan), Azenta US Inc. (US), Adaptive Biotechnologies (US), BGI Group (China), Personalis, Inc. (US), QIAGEN (Netherlands), Tecan Trading AG (Switzerland), and Creative Biolabs (US). These companies are actively investing in research and development, forming strategic partnerships, and engaging in collaborative initiatives to drive innovation, expand their global footprint, and maintain a competitive edge in this rapidly evolving market.
Top three companies:
Illumina, Inc. (US)
Illumina is the world's dominant leader in DNA sequencing, and its short-read technology has been foundational to the genomics revolution. The company provides a comprehensive portfolio of sequencing instruments, from desktop to population-scale platforms, with a business model driven by high-margin, recurring consumable sales. Following its divestiture of GRAIL, Illumina’s strategy is intensely focused on its core sequencing business, driving down costs and pushing for broader adoption in clinical diagnostics, especially oncology. By continuously innovating its platforms, Illumina aims to defend its massive market share and power the future of genomic medicine.
Thermo Fisher Scientific Inc. (US)
Thermo Fisher Scientific is the world leader in serving science, with an immense portfolio of instruments, consumables, and services. In the genomics space, it competes directly with other leaders through its Ion Torrent semiconductor sequencing platform, which offers advantages in speed and targeted applications. Strategically, Thermo Fisher embeds its genomic solutions within its broader life sciences ecosystem, supporting customers from research to diagnostics and biopharma production. By offering a comprehensive, multi-technology approach, the company maintains its powerful position as an end-to-end partner for the entire scientific community, including researchers in India.
PacBio (US)
PacBio is the leading provider of high-fidelity (HiFi) long-read DNA sequencing technology. Unlike short-read methods, its platforms excel at resolving complex genomic regions, providing a completer and more accurate picture of genomes. The company’s core strategy is to drive the adoption of its HiFi sequencing from a research niche into mainstream clinical and discovery applications. By continuously increasing the throughput and lowering the cost of its systems, PacBio is making a compelling case for the value of high-quality, long-read data, solidifying its position as a key innovator in the genomics landscape.
1 INTRODUCTION
1.1 MARKET DEFINITION
1.2 INCLUSIONS & EXCLUSIONS
1.3 STAKEHOLDERS
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET DYNAMICS
3.2.1 DRIVERS
3.2.1.1 Increasing technological advancements
3.2.1.2 Growing focus on personalized/precision medicines
3.2.1.3 Increasing use of immune repertoire sequencing in organ transplant monitoring
3.2.1.4 Increasing applications in autoimmune disease research
3.2.1.5 Rising focus on cancer immunotherapy research
3.2.2 RESTRAINTS
3.2.2.1 Need for high capital investments
3.2.2.2 Limited clinical adoption and validation
3.2.3 OPPORTUNITIES
3.2.3.1 Integration of AI and ML into immune repertoire sequencing
3.2.3.2 Increasing applications in vaccine development
3.2.4 CHALLENGES
3.2.4.1 Variations in regulatory frameworks and international trade dynamics
3.2.4.2 Lack of workflow and data standardization
3.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
3.4 SUPPLY CHAIN ANALYSIS
3.5 VALUE CHAIN ANALYSIS
3.6 ECOSYSTEM ANALYSIS
3.6.1 ROLE IN ECOSYSTEM
3.6.1.1 Product providers
3.6.1.2 Service providers
3.6.1.3 End users
3.7 TECHNOLOGY ANALYSIS
3.7.1 KEY TECHNOLOGIES
3.7.1.1 High-throughput sequencing
3.7.1.2 Nanopore sequencing
3.7.1.3 Single-molecule real-time (SMRT) sequencing
3.7.2 COMPLEMENTARY TECHNOLOGIES
3.7.2.1 Bioinformatics and data analysis platforms
3.7.2.2 Multiplex PCR
3.7.2.3 5’RACE
3.7.3 ADJACENT TECHNOLOGIES
3.7.3.1 Multi-omics integration
3.7.3.2 Spatial genomics and transcriptomics
3.7.3.3 Single-cell sequencing technologies
3.8 PATENT ANALYSIS
3.9 PORTER’S FIVE FORCES ANALYSIS
3.9.1 THREAT OF NEW ENTRANTS
3.9.2 THREAT OF SUBSTITUTES
3.9.3 BARGAINING POWER OF BUYERS
3.9.4 BARGAINING POWER OF SUPPLIERS
3.9.5 INTENSITY OF COMPETITIVE RIVALRY
3.10 IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET
4 COMPETITIVE LANDSCAPE
4.1 INTRODUCTION
4.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022?2025
4.3 REVENUE ANALYSIS, 2022?2024
4.4 MARKET SHARE ANALYSIS, 2024
4.5 COMPANY VALUATION & FINANCIAL METRICS
4.5.1 COMPANY VALUATION
4.5.2 FINANCIAL METRICS
4.6 BRAND/PRODUCT COMPARISON
4.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
4.7.1 STARS
4.7.2 EMERGING LEADERS
4.7.3 PERVASIVE PLAYERS
4.7.4 PARTICIPANTS
4.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
4.7.5.1 Company footprint
4.7.5.2 Region footprint
4.7.5.3 Product and service footprint
4.7.5.4 Application footprint
4.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
4.8.1 PROGRESSIVE COMPANIES
4.8.2 RESPONSIVE COMPANIES
4.8.3 DYNAMIC COMPANIES
4.8.4 STARTING BLOCKS
4.8.5 COMPETITIVE BENCHMARKING
4.8.5.1 Detailed list of key startups/SMEs
4.8.5.2 Competitive benchmarking of key startups/SMEs
4.9 COMPETITIVE SCENARIO
4.9.1 PRODUCT LAUNCHES/APPROVALS/UPGRADES
4.9.2 DEALS
4.9.3 EXPANSIONS
5 COMPANY PROFILES
5.1 KEY PLAYERS
5.1.1 ILLUMINA, INC.
5.1.1.1 Business overview
5.1.1.2 Products/Services/Solutions offered
5.1.1.3 Recent developments
5.1.1.3.1 Product launches/approvals/upgrades
5.1.1.3.2 Deals
5.1.1.3.3 Expansions
5.1.1.4 MnM view
5.1.1.4.1 Key strengths
5.1.1.4.2 Strategic choices
5.1.1.4.3 Weaknesses & competitive threats
5.1.2 THERMO FISHER SCIENTIFIC INC.
5.1.2.1 Business overview
5.1.2.2 Products/Services/Solutions offered
5.1.2.3 Recent developments
5.1.2.3.1 Product launches/approvals/upgrades
5.1.2.3.2 Deals
5.1.2.3.3 Expansions
5.1.2.4 MnM view
5.1.2.4.1 Key strengths
5.1.2.4.2 Strategic choices
5.1.2.4.3 Weaknesses & competitive threats
5.1.3 PACBIO
5.1.3.1 Business overview
5.1.3.2 Products/Services/Solutions offered
5.1.3.3 Recent developments
5.1.3.3.1 Product launches/approvals/upgrades
5.1.3.3.2 Deals
5.1.3.3.3 Expansions
5.1.3.4 MnM view
5.1.3.4.1 Key strengths
5.1.3.4.2 Strategic choices
5.1.3.4.3 Weaknesses & competitive threats
5.1.4 OXFORD NANOPORE TECHNOLOGIES PLC
5.1.4.1 Business overview
5.1.4.2 Products/Services/Solutions offered
5.1.4.3 Recent developments
5.1.4.3.1 Product launches/approvals/upgrades
5.1.4.3.2 Deals
5.1.4.4 MnM view
5.1.4.4.1 Key strengths
5.1.4.4.2 Strategic choices
5.1.4.4.3 Weaknesses & competitive threats
5.1.5 10X GENOMICS
5.1.5.1 Business overview
5.1.5.2 Products/Services/Solutions offered
5.1.5.3 Recent developments
5.1.5.3.1 Product launches/approvals/upgrades
5.1.5.4 MnM view
5.1.5.4.1 Key strengths
5.1.5.4.2 Strategic choices
5.1.5.4.3 Weaknesses & competitive threats
5.1.6 QIAGEN
5.1.6.1 Business overview
5.1.6.2 Products/Services/Solutions offered
5.1.6.3 Recent developments
5.1.6.3.1 Product launches/approvals/upgrades
5.1.6.3.2 Deals
5.1.6.3.3 Expansions
5.1.7 AGILENT TECHNOLOGIES
5.1.7.1 Business overview
5.1.7.2 Products/Services/Solutions offered
5.1.7.3 Recent developments
5.1.7.3.1 Deals
5.1.7.3.2 Expansions
5.1.8 DANAHER CORPORATION
5.1.8.1 Business overview
5.1.8.2 Products/Services/Solutions offered
5.1.8.3 Recent developments
5.1.8.3.1 Deals
5.1.9 TAKARA BIO INC.
5.1.9.1 Business overview
5.1.9.2 Products/Services/Solutions offered
5.1.9.3 Recent developments
5.1.9.3.1 Deals
5.1.10 ADAPTIVE BIOTECHNOLOGIES
5.1.10.1 Business overview
5.1.10.2 Products/Services/Solutions offered
5.1.11 BGI GROUP
5.1.11.1 Business overview
5.1.11.2 Products/Services/Solutions offered
5.1.11.3 Recent developments
5.1.11.3.1 Product launches/approvals/upgrades
5.1.11.3.2 Deals
5.1.11.3.3 Other developments
5.1.12 TECAN TRADING AG
5.1.12.1 Business overview
5.1.12.2 Products/Services/Solutions offered
5.1.12.3 Recent developments
5.1.12.3.1 Deals
5.1.13 AZENTA US INC.
5.1.13.1 Business overview
5.1.13.2 Products/Services/Solutions offered
5.1.14 PERSONALIS, INC.
5.1.14.1 Business overview
5.1.14.2 Products/Services/Solutions offered
5.1.14.3 Recent developments
5.1.14.3.1 Deals
5.1.14.3.2 Other developments
5.1.15 CREATIVE BIOLABS
5.1.15.1 Business overview
5.1.15.2 Products/Services/Solutions offered
5.2 OTHER PLAYERS
5.2.1 CELEMICS, INC.
5.2.2 CELLCARTA
5.2.3 IREPERTOIRE, INC.
5.2.4 NEW ENGLAND BIOLABS
5.2.5 CERBA RESEARCH
5.2.6 CEGAT GMBH
5.2.7 ELEMENT BIOSCIENCES
5.2.8 SEQALIS
5.2.9 SYNBIO TECHNOLOGIES
5.2.10 MEDGENOME
5.2.11 ENPICOM
6 APPENDIX
6.1 RESEARCH METHODOLOGY
6.1.1 RESEARCH DATA
6.1.1.1 Secondary data
6.1.1.2 Primary data
6.1.2 STUDY ASSUMPTIONS
6.1.3 RESEARCH LIMITATIONS
6.1.4 RISK ANALYSIS
6.2 COMPANY EVALUATION MATRIX: METHODOLOGY
6.3 AUTHOR DETAILS
1.1 MARKET DEFINITION
1.2 INCLUSIONS & EXCLUSIONS
1.3 STAKEHOLDERS
2 EXECUTIVE SUMMARY
3 MARKET OVERVIEW
3.1 INTRODUCTION
3.2 MARKET DYNAMICS
3.2.1 DRIVERS
3.2.1.1 Increasing technological advancements
3.2.1.2 Growing focus on personalized/precision medicines
3.2.1.3 Increasing use of immune repertoire sequencing in organ transplant monitoring
3.2.1.4 Increasing applications in autoimmune disease research
3.2.1.5 Rising focus on cancer immunotherapy research
3.2.2 RESTRAINTS
3.2.2.1 Need for high capital investments
3.2.2.2 Limited clinical adoption and validation
3.2.3 OPPORTUNITIES
3.2.3.1 Integration of AI and ML into immune repertoire sequencing
3.2.3.2 Increasing applications in vaccine development
3.2.4 CHALLENGES
3.2.4.1 Variations in regulatory frameworks and international trade dynamics
3.2.4.2 Lack of workflow and data standardization
3.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
3.4 SUPPLY CHAIN ANALYSIS
3.5 VALUE CHAIN ANALYSIS
3.6 ECOSYSTEM ANALYSIS
3.6.1 ROLE IN ECOSYSTEM
3.6.1.1 Product providers
3.6.1.2 Service providers
3.6.1.3 End users
3.7 TECHNOLOGY ANALYSIS
3.7.1 KEY TECHNOLOGIES
3.7.1.1 High-throughput sequencing
3.7.1.2 Nanopore sequencing
3.7.1.3 Single-molecule real-time (SMRT) sequencing
3.7.2 COMPLEMENTARY TECHNOLOGIES
3.7.2.1 Bioinformatics and data analysis platforms
3.7.2.2 Multiplex PCR
3.7.2.3 5’RACE
3.7.3 ADJACENT TECHNOLOGIES
3.7.3.1 Multi-omics integration
3.7.3.2 Spatial genomics and transcriptomics
3.7.3.3 Single-cell sequencing technologies
3.8 PATENT ANALYSIS
3.9 PORTER’S FIVE FORCES ANALYSIS
3.9.1 THREAT OF NEW ENTRANTS
3.9.2 THREAT OF SUBSTITUTES
3.9.3 BARGAINING POWER OF BUYERS
3.9.4 BARGAINING POWER OF SUPPLIERS
3.9.5 INTENSITY OF COMPETITIVE RIVALRY
3.10 IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET
4 COMPETITIVE LANDSCAPE
4.1 INTRODUCTION
4.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022?2025
4.3 REVENUE ANALYSIS, 2022?2024
4.4 MARKET SHARE ANALYSIS, 2024
4.5 COMPANY VALUATION & FINANCIAL METRICS
4.5.1 COMPANY VALUATION
4.5.2 FINANCIAL METRICS
4.6 BRAND/PRODUCT COMPARISON
4.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
4.7.1 STARS
4.7.2 EMERGING LEADERS
4.7.3 PERVASIVE PLAYERS
4.7.4 PARTICIPANTS
4.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
4.7.5.1 Company footprint
4.7.5.2 Region footprint
4.7.5.3 Product and service footprint
4.7.5.4 Application footprint
4.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
4.8.1 PROGRESSIVE COMPANIES
4.8.2 RESPONSIVE COMPANIES
4.8.3 DYNAMIC COMPANIES
4.8.4 STARTING BLOCKS
4.8.5 COMPETITIVE BENCHMARKING
4.8.5.1 Detailed list of key startups/SMEs
4.8.5.2 Competitive benchmarking of key startups/SMEs
4.9 COMPETITIVE SCENARIO
4.9.1 PRODUCT LAUNCHES/APPROVALS/UPGRADES
4.9.2 DEALS
4.9.3 EXPANSIONS
5 COMPANY PROFILES
5.1 KEY PLAYERS
5.1.1 ILLUMINA, INC.
5.1.1.1 Business overview
5.1.1.2 Products/Services/Solutions offered
5.1.1.3 Recent developments
5.1.1.3.1 Product launches/approvals/upgrades
5.1.1.3.2 Deals
5.1.1.3.3 Expansions
5.1.1.4 MnM view
5.1.1.4.1 Key strengths
5.1.1.4.2 Strategic choices
5.1.1.4.3 Weaknesses & competitive threats
5.1.2 THERMO FISHER SCIENTIFIC INC.
5.1.2.1 Business overview
5.1.2.2 Products/Services/Solutions offered
5.1.2.3 Recent developments
5.1.2.3.1 Product launches/approvals/upgrades
5.1.2.3.2 Deals
5.1.2.3.3 Expansions
5.1.2.4 MnM view
5.1.2.4.1 Key strengths
5.1.2.4.2 Strategic choices
5.1.2.4.3 Weaknesses & competitive threats
5.1.3 PACBIO
5.1.3.1 Business overview
5.1.3.2 Products/Services/Solutions offered
5.1.3.3 Recent developments
5.1.3.3.1 Product launches/approvals/upgrades
5.1.3.3.2 Deals
5.1.3.3.3 Expansions
5.1.3.4 MnM view
5.1.3.4.1 Key strengths
5.1.3.4.2 Strategic choices
5.1.3.4.3 Weaknesses & competitive threats
5.1.4 OXFORD NANOPORE TECHNOLOGIES PLC
5.1.4.1 Business overview
5.1.4.2 Products/Services/Solutions offered
5.1.4.3 Recent developments
5.1.4.3.1 Product launches/approvals/upgrades
5.1.4.3.2 Deals
5.1.4.4 MnM view
5.1.4.4.1 Key strengths
5.1.4.4.2 Strategic choices
5.1.4.4.3 Weaknesses & competitive threats
5.1.5 10X GENOMICS
5.1.5.1 Business overview
5.1.5.2 Products/Services/Solutions offered
5.1.5.3 Recent developments
5.1.5.3.1 Product launches/approvals/upgrades
5.1.5.4 MnM view
5.1.5.4.1 Key strengths
5.1.5.4.2 Strategic choices
5.1.5.4.3 Weaknesses & competitive threats
5.1.6 QIAGEN
5.1.6.1 Business overview
5.1.6.2 Products/Services/Solutions offered
5.1.6.3 Recent developments
5.1.6.3.1 Product launches/approvals/upgrades
5.1.6.3.2 Deals
5.1.6.3.3 Expansions
5.1.7 AGILENT TECHNOLOGIES
5.1.7.1 Business overview
5.1.7.2 Products/Services/Solutions offered
5.1.7.3 Recent developments
5.1.7.3.1 Deals
5.1.7.3.2 Expansions
5.1.8 DANAHER CORPORATION
5.1.8.1 Business overview
5.1.8.2 Products/Services/Solutions offered
5.1.8.3 Recent developments
5.1.8.3.1 Deals
5.1.9 TAKARA BIO INC.
5.1.9.1 Business overview
5.1.9.2 Products/Services/Solutions offered
5.1.9.3 Recent developments
5.1.9.3.1 Deals
5.1.10 ADAPTIVE BIOTECHNOLOGIES
5.1.10.1 Business overview
5.1.10.2 Products/Services/Solutions offered
5.1.11 BGI GROUP
5.1.11.1 Business overview
5.1.11.2 Products/Services/Solutions offered
5.1.11.3 Recent developments
5.1.11.3.1 Product launches/approvals/upgrades
5.1.11.3.2 Deals
5.1.11.3.3 Other developments
5.1.12 TECAN TRADING AG
5.1.12.1 Business overview
5.1.12.2 Products/Services/Solutions offered
5.1.12.3 Recent developments
5.1.12.3.1 Deals
5.1.13 AZENTA US INC.
5.1.13.1 Business overview
5.1.13.2 Products/Services/Solutions offered
5.1.14 PERSONALIS, INC.
5.1.14.1 Business overview
5.1.14.2 Products/Services/Solutions offered
5.1.14.3 Recent developments
5.1.14.3.1 Deals
5.1.14.3.2 Other developments
5.1.15 CREATIVE BIOLABS
5.1.15.1 Business overview
5.1.15.2 Products/Services/Solutions offered
5.2 OTHER PLAYERS
5.2.1 CELEMICS, INC.
5.2.2 CELLCARTA
5.2.3 IREPERTOIRE, INC.
5.2.4 NEW ENGLAND BIOLABS
5.2.5 CERBA RESEARCH
5.2.6 CEGAT GMBH
5.2.7 ELEMENT BIOSCIENCES
5.2.8 SEQALIS
5.2.9 SYNBIO TECHNOLOGIES
5.2.10 MEDGENOME
5.2.11 ENPICOM
6 APPENDIX
6.1 RESEARCH METHODOLOGY
6.1.1 RESEARCH DATA
6.1.1.1 Secondary data
6.1.1.2 Primary data
6.1.2 STUDY ASSUMPTIONS
6.1.3 RESEARCH LIMITATIONS
6.1.4 RISK ANALYSIS
6.2 COMPANY EVALUATION MATRIX: METHODOLOGY
6.3 AUTHOR DETAILS
LIST OF TABLES
TABLE 1 IMMUNE REPERTOIRE SEQUENCING MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 IMMUNE REPERTOIRE SEQUENCING MARKET: IMPACT ANALYSIS
TABLE 3 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT PROVIDERS
TABLE 4 IMMUNE REPERTOIRE SEQUENCING MARKET: SERVICE PROVIDERS
TABLE 5 IMMUNE REPERTOIRE SEQUENCING MARKET: END USERS
TABLE 6 INNOVATIONS AND PATENT REGISTRATIONS, 2024–2025
TABLE 7 IMMUNE REPERTOIRE SEQUENCING MARKET: PORTER’S FIVE FORCES
TABLE 8 IMMUNE REPERTOIRE SEQUENCING MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2022?2025
TABLE 9 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: DEGREE OF COMPETITION, 2024
TABLE 10 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET: DEGREE OF COMPETITION, 2024
TABLE 11 IMMUNE REPERTOIRE SEQUENCING MARKET: REGION FOOTPRINT
TABLE 12 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT AND SERVICE FOOTPRINT
TABLE 13 IMMUNE REPERTOIRE SEQUENCING MARKET: APPLICATION FOOTPRINT
TABLE 14 IMMUNE REPERTOIRE SEQUENCING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 15 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 16 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 17 IMMUNE REPERTOIRE SEQUENCING MARKET: DEALS, JANUARY 2022–MARCH 2025
TABLE 18 IMMUNE REPERTOIRE SEQUENCING MARKET: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 19 ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 20 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 21 ILLUMINA, INC.: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 22 ILLUMINA, INC.: DEALS, JANUARY 2022–MARCH 2025
TABLE 23 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 24 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 25 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 26 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 27 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–MARCH 2025
TABLE 28 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 29 PACBIO: COMPANY OVERVIEW
TABLE 30 PACBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 31 PACBIO: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 32 PACBIO: DEALS, JANUARY 2022–MARCH 2025
TABLE 33 PACBIO: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 34 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW
TABLE 35 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 36 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 37 OXFORD NANOPORE TECHNOLOGIES PLC: DEALS, JANUARY 2022–MARCH 2025
TABLE 38 10X GENOMICS: COMPANY OVERVIEW
TABLE 39 10X GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 40 10X GENOMICS: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 41 QIAGEN: COMPANY OVERVIEW
TABLE 42 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 43 QIAGEN: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 44 QIAGEN: DEALS, JANUARY 2022–MARCH 2025
TABLE 45 QIAGEN: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 46 AGILENT TECHNOLOGIES: COMPANY OVERVIEW
TABLE 47 AGILENT TECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 48 AGILENT TECHNOLOGIES: DEALS, JANUARY 2022–MARCH 2025
TABLE 49 AGILENT TECHNOLOGIES: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 50 DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 51 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 52 DANAHER CORPORATION: DEALS, JANUARY 2022–MARCH 2025
TABLE 53 TAKARA BIO INC.: COMPANY OVERVIEW
TABLE 54 TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 55 TAKARA BIO INC.: DEALS, JANUARY 2022–MARCH 2025
TABLE 56 ADAPTIVE BIOTECHNOLOGIES: COMPANY OVERVIEW
TABLE 57 ADAPTIVE BIOTECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 58 BGI GROUP: COMPANY OVERVIEW
TABLE 59 BGI GROUP: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 60 BGI GROUP: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 61 BGI GROUP: DEALS, JANUARY 2022–MARCH 2025
TABLE 62 BGI GROUP: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
TABLE 63 TECAN TRADING AG: COMPANY OVERVIEW
TABLE 64 TECAN TRADING AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 65 TECAN TRADING AG: DEALS, JANUARY 2022–MARCH 2025
TABLE 66 AZENTA US INC.: COMPANY OVERVIEW
TABLE 67 AZENTA US INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 68 PERSONALIS, INC.: COMPANY OVERVIEW
TABLE 69 PERSONALIS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 70 PERSONALIS, INC.: DEALS, JANUARY 2022–MARCH 2025
TABLE 71 PERSONALIS, INC.: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
TABLE 72 CREATIVE BIOLABS: COMPANY OVERVIEW
TABLE 73 CREATIVE BIOLABS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 74 CELEMICS, INC.: COMPANY OVERVIEW
TABLE 75 CELLCARTA: COMPANY OVERVIEW
TABLE 76 IREPERTOIRE, INC.: COMPANY OVERVIEW
TABLE 77 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
TABLE 78 CERBA RESEARCH: COMPANY OVERVIEW
TABLE 79 CEGAT GMBH: COMPANY OVERVIEW
TABLE 80 ELEMENT BIOSCIENCES: COMPANY OVERVIEW
TABLE 81 SEQALIS: COMPANY OVERVIEW
TABLE 82 SYNBIO TECHNOLOGIES: COMPANY OVERVIEW
TABLE 83 MEDGENOME: COMPANY OVERVIEW
TABLE 84 ENPICOM: COMPANY OVERVIEW
TABLE 85 IMMUNE REPERTOIRE SEQUENCING MARKET: RISK ANALYSIS
TABLE 1 IMMUNE REPERTOIRE SEQUENCING MARKET: INCLUSIONS & EXCLUSIONS
TABLE 2 IMMUNE REPERTOIRE SEQUENCING MARKET: IMPACT ANALYSIS
TABLE 3 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT PROVIDERS
TABLE 4 IMMUNE REPERTOIRE SEQUENCING MARKET: SERVICE PROVIDERS
TABLE 5 IMMUNE REPERTOIRE SEQUENCING MARKET: END USERS
TABLE 6 INNOVATIONS AND PATENT REGISTRATIONS, 2024–2025
TABLE 7 IMMUNE REPERTOIRE SEQUENCING MARKET: PORTER’S FIVE FORCES
TABLE 8 IMMUNE REPERTOIRE SEQUENCING MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2022?2025
TABLE 9 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: DEGREE OF COMPETITION, 2024
TABLE 10 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET: DEGREE OF COMPETITION, 2024
TABLE 11 IMMUNE REPERTOIRE SEQUENCING MARKET: REGION FOOTPRINT
TABLE 12 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT AND SERVICE FOOTPRINT
TABLE 13 IMMUNE REPERTOIRE SEQUENCING MARKET: APPLICATION FOOTPRINT
TABLE 14 IMMUNE REPERTOIRE SEQUENCING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
TABLE 15 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
TABLE 16 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 17 IMMUNE REPERTOIRE SEQUENCING MARKET: DEALS, JANUARY 2022–MARCH 2025
TABLE 18 IMMUNE REPERTOIRE SEQUENCING MARKET: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 19 ILLUMINA, INC.: COMPANY OVERVIEW
TABLE 20 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 21 ILLUMINA, INC.: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 22 ILLUMINA, INC.: DEALS, JANUARY 2022–MARCH 2025
TABLE 23 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 24 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
TABLE 25 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 26 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 27 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022–MARCH 2025
TABLE 28 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 29 PACBIO: COMPANY OVERVIEW
TABLE 30 PACBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 31 PACBIO: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 32 PACBIO: DEALS, JANUARY 2022–MARCH 2025
TABLE 33 PACBIO: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 34 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW
TABLE 35 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 36 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 37 OXFORD NANOPORE TECHNOLOGIES PLC: DEALS, JANUARY 2022–MARCH 2025
TABLE 38 10X GENOMICS: COMPANY OVERVIEW
TABLE 39 10X GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 40 10X GENOMICS: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 41 QIAGEN: COMPANY OVERVIEW
TABLE 42 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 43 QIAGEN: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 44 QIAGEN: DEALS, JANUARY 2022–MARCH 2025
TABLE 45 QIAGEN: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 46 AGILENT TECHNOLOGIES: COMPANY OVERVIEW
TABLE 47 AGILENT TECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 48 AGILENT TECHNOLOGIES: DEALS, JANUARY 2022–MARCH 2025
TABLE 49 AGILENT TECHNOLOGIES: EXPANSIONS, JANUARY 2022–MARCH 2025
TABLE 50 DANAHER CORPORATION: COMPANY OVERVIEW
TABLE 51 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 52 DANAHER CORPORATION: DEALS, JANUARY 2022–MARCH 2025
TABLE 53 TAKARA BIO INC.: COMPANY OVERVIEW
TABLE 54 TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 55 TAKARA BIO INC.: DEALS, JANUARY 2022–MARCH 2025
TABLE 56 ADAPTIVE BIOTECHNOLOGIES: COMPANY OVERVIEW
TABLE 57 ADAPTIVE BIOTECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 58 BGI GROUP: COMPANY OVERVIEW
TABLE 59 BGI GROUP: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 60 BGI GROUP: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022–MARCH 2025
TABLE 61 BGI GROUP: DEALS, JANUARY 2022–MARCH 2025
TABLE 62 BGI GROUP: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
TABLE 63 TECAN TRADING AG: COMPANY OVERVIEW
TABLE 64 TECAN TRADING AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 65 TECAN TRADING AG: DEALS, JANUARY 2022–MARCH 2025
TABLE 66 AZENTA US INC.: COMPANY OVERVIEW
TABLE 67 AZENTA US INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 68 PERSONALIS, INC.: COMPANY OVERVIEW
TABLE 69 PERSONALIS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 70 PERSONALIS, INC.: DEALS, JANUARY 2022–MARCH 2025
TABLE 71 PERSONALIS, INC.: OTHER DEVELOPMENTS, JANUARY 2022–MARCH 2025
TABLE 72 CREATIVE BIOLABS: COMPANY OVERVIEW
TABLE 73 CREATIVE BIOLABS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
TABLE 74 CELEMICS, INC.: COMPANY OVERVIEW
TABLE 75 CELLCARTA: COMPANY OVERVIEW
TABLE 76 IREPERTOIRE, INC.: COMPANY OVERVIEW
TABLE 77 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
TABLE 78 CERBA RESEARCH: COMPANY OVERVIEW
TABLE 79 CEGAT GMBH: COMPANY OVERVIEW
TABLE 80 ELEMENT BIOSCIENCES: COMPANY OVERVIEW
TABLE 81 SEQALIS: COMPANY OVERVIEW
TABLE 82 SYNBIO TECHNOLOGIES: COMPANY OVERVIEW
TABLE 83 MEDGENOME: COMPANY OVERVIEW
TABLE 84 ENPICOM: COMPANY OVERVIEW
TABLE 85 IMMUNE REPERTOIRE SEQUENCING MARKET: RISK ANALYSIS
LIST OF FIGURES
FIGURE 1 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
FIGURE 2 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
FIGURE 3 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2025 VS. 2030 (USD MILLION)
FIGURE 4 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
FIGURE 5 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 6 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 7 IMMUNE REPERTOIRE SEQUENCING MARKET: REGIONAL SNAPSHOT
FIGURE 8 IMMUNE REPERTOIRE SEQUENCING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 9 IMMUNE REPERTOIRE SEQUENCING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 10 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 11 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: VALUE CHAIN ANALYSIS
FIGURE 12 IMMUNE REPERTOIRE SEQUENCING MARKET: ECOSYSTEM ANALYSIS
FIGURE 13 PATENT APPLICATIONS FOR IMMUNE REPERTOIRE SEQUENCING (JANUARY 2015–DECEMBER 2024)
FIGURE 14 IMMUNE REPERTOIRE SEQUENCING MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15 IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET
FIGURE 16 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET (2022?2024)
FIGURE 17 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET (2022?2024)
FIGURE 18 MARKET SHARE ANALYSIS OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, 2024
FIGURE 19 MARKET SHARE ANALYSIS OF IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, 2024
FIGURE 20 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 21 EV/EBITDA OF KEY PLAYERS
FIGURE 22 IMMUNE REPERTOIRE SEQUENCING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 23 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 24 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY FOOTPRINT
FIGURE 25 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 26 ILLUMINA, INC.: COMPANY SNAPSHOT
FIGURE 27 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
FIGURE 28 PACBIO: COMPANY SNAPSHOT
FIGURE 29 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT
FIGURE 30 10X GENOMICS: COMPANY SNAPSHOT
FIGURE 31 QIAGEN: COMPANY SNAPSHOT
FIGURE 32 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
FIGURE 33 DANAHER CORPORATION: COMPANY SNAPSHOT
FIGURE 34 TAKARA BIO INC.: COMPANY SNAPSHOT
FIGURE 35 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT
FIGURE 36 TECAN TRADING AG: COMPANY SNAPSHOT
FIGURE 37 AZENTA US INC.: COMPANY SNAPSHOT
FIGURE 38 PERSONALIS, INC.: COMPANY SNAPSHOT
FIGURE 39 IMMUNE REPERTOIRE SEQUENCING MARKET: RESEARCH DESIGN
FIGURE 1 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
FIGURE 2 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
FIGURE 3 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2025 VS. 2030 (USD MILLION)
FIGURE 4 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
FIGURE 5 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 6 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
FIGURE 7 IMMUNE REPERTOIRE SEQUENCING MARKET: REGIONAL SNAPSHOT
FIGURE 8 IMMUNE REPERTOIRE SEQUENCING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
FIGURE 9 IMMUNE REPERTOIRE SEQUENCING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 10 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: SUPPLY CHAIN ANALYSIS
FIGURE 11 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: VALUE CHAIN ANALYSIS
FIGURE 12 IMMUNE REPERTOIRE SEQUENCING MARKET: ECOSYSTEM ANALYSIS
FIGURE 13 PATENT APPLICATIONS FOR IMMUNE REPERTOIRE SEQUENCING (JANUARY 2015–DECEMBER 2024)
FIGURE 14 IMMUNE REPERTOIRE SEQUENCING MARKET: PORTER’S FIVE FORCES ANALYSIS
FIGURE 15 IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET
FIGURE 16 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET (2022?2024)
FIGURE 17 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET (2022?2024)
FIGURE 18 MARKET SHARE ANALYSIS OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, 2024
FIGURE 19 MARKET SHARE ANALYSIS OF IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, 2024
FIGURE 20 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
FIGURE 21 EV/EBITDA OF KEY PLAYERS
FIGURE 22 IMMUNE REPERTOIRE SEQUENCING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
FIGURE 23 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
FIGURE 24 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY FOOTPRINT
FIGURE 25 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
FIGURE 26 ILLUMINA, INC.: COMPANY SNAPSHOT
FIGURE 27 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
FIGURE 28 PACBIO: COMPANY SNAPSHOT
FIGURE 29 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT
FIGURE 30 10X GENOMICS: COMPANY SNAPSHOT
FIGURE 31 QIAGEN: COMPANY SNAPSHOT
FIGURE 32 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
FIGURE 33 DANAHER CORPORATION: COMPANY SNAPSHOT
FIGURE 34 TAKARA BIO INC.: COMPANY SNAPSHOT
FIGURE 35 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT
FIGURE 36 TECAN TRADING AG: COMPANY SNAPSHOT
FIGURE 37 AZENTA US INC.: COMPANY SNAPSHOT
FIGURE 38 PERSONALIS, INC.: COMPANY SNAPSHOT
FIGURE 39 IMMUNE REPERTOIRE SEQUENCING MARKET: RESEARCH DESIGN
